Financings

• Aeterna Zentaris Inc. completed its previously reported $12.1 million registered direct offering.

• BioSante Pharmaceuticals Inc. netted $14.2 million in a registered direct offering of stock and warrants.

• Cadence Pharmaceuticals Inc. secured a $30 million loan facility.

• Incline Therapeutics Inc. raised $43 million in a Series A round for a needle-free analgesic.

• Nereus Pharmaceuticals Inc. raised $20 million from existing venture investors.

• Precision Therapeutics Inc. raised $35 million in a Series D financing.

Deals

• BioLineRx Ltd. signed a $365 million regional deal for antipsychotic BL-1020 with Cypress Bioscience Inc.

• Cadence Pharmaceuticals Inc. signed an option to acquire Incline Therapeutics Inc.

• Diamyd Medical AB landed a $625 million diabetes deal with Johnson & Johnson.

• Dyax Corp. inked a $100 million regional deal for hereditary angioedema drug ecallantide with Sigma-Tau SpA.

• Exelixis Inc. regained the rights to MET inhibitor XL184 from Bristol-Myers Squibb Co.

• Metabolex Inc. signed a $330 million diabetes deal with Johnson & Johnson.

• Regulus Therapeutics Inc. landed a $750 million microRNA deal with Sanofi-Aventis Group SA.

• Santaris Pharma A/S and miRagen Therapeutics Inc. partnered to develop microRNA drugs for cardiovascular disease (no terms).

• Valeant Pharmaceuticals International Inc. and Biovail Corp. agreed to a $3.3 billion merger.

. . . And More

• BioWorld Today included coverage from the 11th Congress of the European League Against Rheumatism (EULAR), the Endocrine Society annual meeting (ENDO) and the American Headache Society (AHS) annual meeting.

• Affymax Inc. reported mixed data from four Phase III trials of Hematide for anemia.

• Genentech Inc./Roche AG gained FDA approval of Lucentis (ranibizumab) for macular edema following retinal vein occlusion.

• Ipsen SA and Roche AG said side effects have delayed Phase III diabetes drug taspoglutide.

• Novartis AG got FDA approval of Tasigna (nilotinib) for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

• Pfizer Inc. voluntary withdrew acute myeloid leukemia drug Mylotarg (gemtuzumab ozogamicin) from the market.

• Pfizer Inc. suspended development of tanezumab for osteoarthritis pain.

• SkyePharma plc said it doubts it will get FDA approval of asthma drug Flutiform (fluticasone propionate/formoterol fumarate).